Octreotide lar

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerCirrhosisAdenomaAutosomal Dominant Polycystic Kidney DiseaseAcromegalyCarcinoid Syndrome

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Octreotide lar

Novartis

Approved

12

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

14

Viagra

VViatris Specialty LLC

Preclinical

15

Duragesic

CCephalon

Preclinical

16

Prednisone/prednisolone

Roche

Preclinical

37

Triptorelin Pamoate

Ipsen

Preclinical

28

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Acromegaly6 trials

Ultrasound Guided Octreotide LAR Injection in Acromegaly

Completed·—·Phase 4·NCT00552071·15 enrolled

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Completed·Novartis·Phase 3·NCT01137682·198 enrolled

Prediction of Tumor Shrinkage in Acromegaly

Completed·FFederico II University··NCT00616408·61 enrolled

Show 3 more trials

Acromegaly Combination Treatment Study

Terminated·—·N/A·NCT01538966·76 enrolled

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Completed·Novartis·Phase 3·NCT00225979·100 enrolled

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Completed·FFederico II University·Phase 4·NCT00461149·50 enrolled

Safety and Efficacy2 trials

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

Recruiting·HHTA Co., Ltd.·Phase 3·NCT07057622·184 enrolled

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Completed·Novartis·Phase 3·NCT00128232·100 enrolled

Neuroendocrine Tumors2 trials

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Completed·CCarmen Schade-Brittinger·Phase 3·NCT00171873·85 enrolled

High Dose Somatostatin Analogues in Neuroendocrine Tumors

Completed·FFederico II University·Phase 2·NCT00990535·28 enrolled

Treatment2 trials

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Completed·AAdvanced Accelerator Applications·Phase 3·NCT01578239·231 enrolled

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Active, not recruiting·SSinotau Pharmaceutical Group·Phase 3·NCT05459844·196 enrolled

Efficacy and Safety2 trials

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Recruiting·Novartis·Phase 3·NCT06784752·240 enrolled

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Active, not recruiting·CCamurus AB·Phase 3·NCT05050942·332 enrolled

12 more indications

Maintenance Treatment1 trial

Octreotide LAR as Maintenance Treatment for Patients With NEC

Unknown status·PPeking University·Phase 2·NCT02409849·92 enrolled

Bleeding1 trial

Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber

Unknown status·RRadboud University Medical Center·Phase 2·NCT02874326·15 enrolled

ADPKD1 trial

Tolvaptan-Octreotide LAR Combination in ADPKD

Completed·Mario Negri Institute for Pharmacological Research·Phase 2·NCT03541447·20 enrolled

Carcinoid Syndrome1 trial

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01886287·2 enrolled

Cystic1 trial

Everolimus and LongActing Octreotide Trial in Polycystic Livers

Completed·RRadboud University Medical Center·Phase 2·NCT01157858·44 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

Completed·Mario Negri Institute for Pharmacological Research·Phase 3·NCT01377246·100 enrolled

Real-world Study1 trial

Real-world Study on Adjuvant Octreotide Therapy in pNETs

Completed·—·N/A·NCT06080204·411 enrolled

Adenoma1 trial

Surgical Debulking of Pituitary Adenomas

Completed·NNYU Langone Health·Phase 4·NCT01371643·41 enrolled

Peritoneal Carcinomatosis1 trial

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Completed·Novartis·Phase 2·NCT00332696·64 enrolled

Advanced1 trial

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT01567488·43 enrolled

Prostate Cancer1 trial

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Completed·Novartis·Phase 2·NCT00166725·40 enrolled

Cirrhosis1 trial

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00108355·29 enrolled

Details

Drug Info

Related News